<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623193</url>
  </required_header>
  <id_info>
    <org_study_id>ABC Trial</org_study_id>
    <nct_id>NCT01623193</nct_id>
  </id_info>
  <brief_title>The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study</brief_title>
  <acronym>ABC</acronym>
  <official_title>The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stacy OBlenes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single centre pilot for a randomized trial comparing all-blood cardioplegia
      to more dilute 4:1 blood cardioplegia during cardiac surgery. The hypothesis is that
      all-blood cardioplegia will be associated with less blood transfusion and better cardiac
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single centre randomized, double blind, 2 arm, parallel group pilot study comparing
      all-blood cardioplegia to 4:1 blood cardioplegia in patients undergoing cardiac surgery. This
      pilot study will support the design of a larger multicentre trial.

      Subjects undergoing cardiac surgery will be randomized to receive either standard of care
      (4:1) or all-blood cardioplegia for myocardial protection. Neither of these cardioplegia
      approaches would be considered investigational. Each is in use at numerous cardiac surgical
      centres around the world. The cardioplegia will be delivered using the Quest medical MPS
      system which is a Health Canada Approved device.

      Clinical endpoints will be evalauted (rate of blood transtransfusion, ICU stay, etcâ€¦). In a
      subset of subjects who meet specific criteria, ventricular function will be evaluated in the
      operating room using the CD Leycom INCA conductance catheter system.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>30 days</time_frame>
    <description>Number of units of packed red blood cells transfused</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-op diastolic function</measure>
    <time_frame>day 1</time_frame>
    <description>Left ventricular chamber stiffness constant measured by conductance catheter in the operating room</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 day</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Ventilation</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lentgh of stay ICU</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay - hospital</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other blood product administration</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hgb - arrival ICU</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hgb - prior to Discharge</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest post op Hgb</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of crystalloid delivered in cardioplegia</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>30 d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate for bleeding</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotrope score</measure>
    <time_frame>30 day</time_frame>
    <description>Score incorporating amount and number of inotropes administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low output syndrome</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin</measure>
    <time_frame>24 hours post op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Composite according to standardized definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-op Ventricular function</measure>
    <time_frame>day 1</time_frame>
    <description>as determined by conductance catheter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive all-blood cardiolpegia for myocardial protection during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>All-blood cardioplegia</intervention_name>
    <description>The treatment group will receive all-blood cardioplegia for myocardial protection during surgery</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard cardioplegia</intervention_name>
    <description>This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients (male and female) undergoing isolated coronary artery bypass grafting,

          -  isolated aortic or mitral repair or replacement, and

          -  combined aortic or mitral valve repair or replacement and

          -  coronary bypass grafting

        Exclusion Criteria:

          -  reoperation,

          -  endocarditis,

          -  dialysis dependant renal failure,

          -  pre-operative ECMO or LVAD support,

          -  contraindication to blood transfusion (ie. Jehovah's Witness), and

          -  use of irreversible anti-platelet (other than ASA) and anticoagulant agents within 48h
             (ie. plavix, dabigitran, GpIIb/IIIa inhibitors, argatroban).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy O'Blenes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacy O'Blenes, MD</last_name>
    <phone>902 473-7890</phone>
    <email>stacy.oblenes@iwk.nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Greg Hirsch, MD</last_name>
    <phone>902 473-7890</phone>
    <email>Greg.Hirsch@dal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy O'Blenes, MD</last_name>
      <phone>902 473-7890</phone>
      <email>stacy.oblenes@iwk.nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Greg Hirsch, MD</last_name>
      <phone>902 473-7890</phone>
      <email>greg.hirsch@dal.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Stacy O'Blenes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Hirsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Stacy OBlenes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cardioplegia</keyword>
  <keyword>Blood transfusion</keyword>
  <keyword>Cardiac function</keyword>
  <keyword>Myocardial edema</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Valve disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

